Myriad Genetics, MRD
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, sequencing-based MRD assays, such as Myriad’s Precise ® MRD test.
Hosted on MSN24d
Protein blood test helps predict myriad of diseasesA single drop of blood might be able to predict the onset of dozens of diseases, a new study claims. Analysis of the protein "signatures" in a droplet of blood can predict 67 diseases, including ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
Myriad Genetics, Inc. engages in the discovery ... that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback